CENTOGENE´s Expertise in Hypomyelinating Leukodystrophy gives New Insights in the Clinical and Genetic Spectrum of the Disease
Using next generation sequencing, CENTOGENE and its international partners were able to characterize new genetic variants in NKX6-2 cases. The two key factors in these rare diseases are the clinical symptoms in larger cohorts and the interaction between the individual mutation and the severity of the disease. Developmental regression is clearly a previously underestimated clinical feature.
“With the continuation from last year, the research focus of the Rare Disease Day 2018 clearly emphasizes that research is the start and basis for every medical routine that follows after. We are heartened that our findings expand on the clinical and genetic understanding of the disease and identified a novel genetic marker associated with this form of HLD,” said Professor Peter Bauer, M.D., CSO of CENTOGENE. “Publications like these highlight the richness of rare disease genetic data captured in our database CentoMD®, the world’s largest mutation database of rare diseases, which can significantly reduce the time needed to diagnose and potentially treat these patients.”
CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with genetic diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database, CentoMD® and solutions for pharmaceutical companies developing life-changing orphan drugs.
As one of the most diversified and largest genetic testing companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients and their families. www.centogene.com; www.centoMD.com
MacDougall Biomedical Communications
Lauren Arnold, 781-235-3060